TR201900852T4 - Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşı yeni immünoterapi. - Google Patents

Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşı yeni immünoterapi. Download PDF

Info

Publication number
TR201900852T4
TR201900852T4 TR2019/00852T TR201900852T TR201900852T4 TR 201900852 T4 TR201900852 T4 TR 201900852T4 TR 2019/00852 T TR2019/00852 T TR 2019/00852T TR 201900852 T TR201900852 T TR 201900852T TR 201900852 T4 TR201900852 T4 TR 201900852T4
Authority
TR
Turkey
Prior art keywords
cells
cell
tumor
peptide
expression
Prior art date
Application number
TR2019/00852T
Other languages
English (en)
Turkish (tr)
Inventor
Schoor Oliver
Hilf Norbert
Weinschenk Toni
Trautwein Claudia
Singh Harpreet
Walter Steffen
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of TR201900852T4 publication Critical patent/TR201900852T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
TR2019/00852T 2008-10-01 2009-09-28 Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşı yeni immünoterapi. TR201900852T4 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP08017921.1A EP2172212B1 (en) 2008-10-01 2008-10-13 Novel immunotherapy against several tumors including neuronal and brain tumors
US10592808P 2008-10-16 2008-10-16

Publications (1)

Publication Number Publication Date
TR201900852T4 true TR201900852T4 (tr) 2019-02-21

Family

ID=40342382

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2019/00852T TR201900852T4 (tr) 2008-10-01 2009-09-28 Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşı yeni immünoterapi.
TR2019/00809T TR201900809T4 (tr) 2008-10-01 2009-09-28 Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşi yeni immünoterapi.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2019/00809T TR201900809T4 (tr) 2008-10-01 2009-09-28 Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşi yeni immünoterapi.

Country Status (24)

Country Link
US (19) US8318677B2 (OSRAM)
EP (12) EP2172211B1 (OSRAM)
JP (10) JP5753783B2 (OSRAM)
KR (6) KR102392070B1 (OSRAM)
CN (3) CN102170900B (OSRAM)
AU (2) AU2009300087B2 (OSRAM)
BR (2) BRPI0920791B8 (OSRAM)
CA (9) CA2739384C (OSRAM)
CY (11) CY1116302T1 (OSRAM)
DK (12) DK2172211T3 (OSRAM)
EA (3) EA023013B1 (OSRAM)
ES (12) ES2536465T3 (OSRAM)
HR (12) HRP20160915T1 (OSRAM)
HU (11) HUE031030T2 (OSRAM)
LT (10) LT2172212T (OSRAM)
MX (3) MX338294B (OSRAM)
NZ (4) NZ591855A (OSRAM)
PL (12) PL2172211T3 (OSRAM)
PT (12) PT2172211E (OSRAM)
RS (12) RS53782B1 (OSRAM)
SI (12) SI2172211T1 (OSRAM)
TR (2) TR201900852T4 (OSRAM)
UA (3) UA125277C2 (OSRAM)
WO (2) WO2010037514A2 (OSRAM)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
PL2183361T3 (pl) * 2007-07-27 2015-10-30 Immatics Biotechnologies Gmbh Innowacyjna immunoterapia przeciwko nowotworom mózgu
ES2342506T3 (es) * 2008-04-30 2010-07-07 Immatics Biotechnologies Gmbh Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP2608799B1 (en) 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2012075490A2 (en) * 2010-12-03 2012-06-07 Duke University Anti-podoplanin antibodies and methods of use
NZ609916A (en) * 2010-12-14 2015-03-27 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US20140154269A1 (en) * 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
CA2847698C (en) 2011-09-14 2020-09-01 Northwestern University Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
US10201521B2 (en) * 2012-01-20 2019-02-12 Del Mar Pharmaceuticals (Bc) Ltd. Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
SI3536334T1 (sl) 2012-05-16 2021-11-30 Stemline Therapeutics Inc. Cepiva proti raku, ki ciljajo na rakave matične celice
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
ES3010561T3 (en) 2013-08-05 2025-04-03 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer including nsclc
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
RS60544B1 (sr) 2014-04-25 2020-08-31 Bluebird Bio Inc Poboljšani metodi za proizvodnju adoptivnih ćelijskih terapija
EP3134432B1 (en) 2014-04-25 2019-12-25 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
JP6613526B2 (ja) * 2014-05-28 2019-12-04 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
US10479975B2 (en) * 2014-06-06 2019-11-19 Bluebird Bio, Inc. Methods of making T cell compositions
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
CN107073087B (zh) * 2014-11-06 2020-09-08 奥塞免疫疗法公司 治疗脑转移瘤的治疗性多种肽t特异性免疫疗法
LT3230321T (lt) 2014-12-12 2019-12-10 Bluebird Bio Inc Bcma chimeriniai antigeno receptoriai
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20192212T4 (hr) 2014-12-23 2022-11-25 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
MY190083A (en) 2015-03-17 2022-03-25 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
JP6985153B2 (ja) * 2015-05-06 2021-12-22 イマティクス バイオテクノロジーズ ゲーエムベーハー 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2016200787A2 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for haemophilus influenzae
PL3319635T3 (pl) 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
MA42294B1 (fr) 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CA3221001A1 (en) * 2015-07-06 2017-01-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
MY199262A (en) 2015-08-28 2023-10-23 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
JP7572700B2 (ja) 2015-10-19 2024-10-24 ユニバーシティ オブ メリーランド ボルチモア 改変ヒト初代血液樹状細胞株を生成するための方法
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
IL298653A (en) * 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
EP4177264A1 (en) 2016-03-16 2023-05-10 Immatics Biotechnologies GmbH Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
JP6989136B2 (ja) * 2016-04-06 2022-01-05 イマティクス バイオテクノロジーズ ゲーエムベーハー Ａｍｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
CN110022889B (zh) * 2016-10-03 2024-05-10 渥太华医院研究所 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法
AU2017355504C1 (en) 2016-11-04 2024-06-20 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
IL303806B2 (en) * 2016-12-22 2024-05-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
US10174122B2 (en) 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) * 2017-02-28 2018-08-30 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
AU2018348165B2 (en) 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US11766455B2 (en) * 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
FI3773689T3 (fi) * 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
CN120843603A (zh) 2018-07-11 2025-10-28 布里格姆妇女医院 用于跨血脑屏障递送试剂的方法和组合物
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
JP7619957B2 (ja) 2019-03-29 2025-01-22 インターベット インターナショナル ベー． フェー． 液体組成物中の生モリクテス綱細菌の安定化
GB2617512B (en) * 2019-04-05 2023-12-27 Earli Inc Improved methods and compositions for synthetic biomarkers
WO2020243193A1 (en) 2019-05-28 2020-12-03 PAIGE.AI, Inc. Systems and methods for processing images to prepare slides for processed images for digital pathology
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
WO2021142300A2 (en) * 2020-01-10 2021-07-15 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
CA3170412A1 (en) * 2020-02-24 2021-09-02 The Regents Of The University Of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113621024A (zh) * 2020-03-18 2021-11-09 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
AU2021249123A1 (en) * 2020-03-31 2022-10-27 Walking Fish Therapeutics Modified B cells and methods of use thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2022047248A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
JP2024509576A (ja) * 2021-03-09 2024-03-04 ボストンジーン コーポレイション 明細胞腎細胞がんを有する患者における治療に対する応答の予測
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) * 2022-03-30 2025-07-24 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
CN120272531B (zh) * 2025-06-10 2025-08-19 鼐济医药科技(杭州)有限公司 一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
ATE157100T1 (de) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
JP2002513381A (ja) * 1996-07-22 2002-05-08 ザ ロックフェラー ユニバーシティー ＨＴＬＶ―Ｉ感染およびＨＴＬＶ―ＩＩ感染を予防するためのｅｎｖ―糖タンパク質ワクチン
WO1998031797A1 (en) 1997-01-15 1998-07-23 Zymogenetics, Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
CA2243984A1 (en) * 1997-02-13 1998-08-20 Smithkline Beecham P.L.C. Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1044263A2 (en) * 1997-12-02 2000-10-18 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO1999055380A1 (en) * 1998-04-27 1999-11-04 Pacific Northwest Cancer Foundation Nr-CAM GENE, NUCLEIC ACIDS AND NUCLEIC ACID PRODUCTS FOR THERAPEUTIC AND DIAGNOSTIC USES FOR TUMORS
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
US20020042386A1 (en) * 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055309A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1317275A1 (de) * 2000-09-06 2003-06-11 Müller, Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7083789B2 (en) * 2000-12-04 2006-08-01 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1379879A2 (en) * 2000-12-08 2004-01-14 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of alzheimer's disease
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
JP2006516258A (ja) * 2002-12-27 2006-06-29 シェンジェンシチンファユアンシンシェンウイヤオカジヨウシャンゴンシ ワクチンおよび抗腫瘍ワクチンを調製する方法
WO2004089300A2 (en) 2003-04-04 2004-10-21 Pharmacyclics, Inc. Sapphyrins and uses thereof
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
US7655751B2 (en) * 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006026569A2 (en) * 2004-08-27 2006-03-09 Northeastern University Comprehensive characterization of complex proteins at trace levels
ES2319286T3 (es) * 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
ES2534752T3 (es) * 2004-12-07 2015-04-27 Toray Industries, Inc. Nuevo péptido antigénico contra el cáncer y utilización del mismo
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
WO2008035350A1 (en) * 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2008039874A2 (en) * 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008109757A2 (en) * 2007-03-06 2008-09-12 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
ES2342506T3 (es) * 2008-04-30 2010-07-07 Immatics Biotechnologies Gmbh Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
EP3757134B1 (en) * 2014-05-28 2024-03-06 NoNO Inc. Chloride salt of tat-nr2b9c
EP3445383A1 (en) 2016-04-21 2019-02-27 Immatics Biotechnologies GmbH Immunotherapy against melanoma and other cancers
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)

Also Published As

Publication number Publication date
JP2017018102A (ja) 2017-01-26
PL2172212T3 (pl) 2017-04-28
US20190010190A1 (en) 2019-01-10
CA2739387C (en) 2019-10-29
KR101756488B1 (ko) 2017-07-11
RS55543B1 (sr) 2017-05-31
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
EP3124043A1 (en) 2017-02-01
JP5855940B2 (ja) 2016-02-09
US8895514B2 (en) 2014-11-25
RS58443B1 (sr) 2019-04-30
NZ603016A (en) 2014-05-30
US8119139B2 (en) 2012-02-21
US11136352B2 (en) 2021-10-05
CN102170900B (zh) 2016-10-26
JP6367266B2 (ja) 2018-08-01
BRPI0920791A2 (pt) 2019-12-10
NZ624533A (en) 2015-09-25
SI3120868T1 (sl) 2020-08-31
US10919931B2 (en) 2021-02-16
DK3106175T3 (da) 2020-06-22
HRP20150223T8 (hr) 2015-07-03
HRP20182151T1 (hr) 2019-02-08
HRP20201228T1 (hr) 2021-02-05
JP6297632B2 (ja) 2018-03-20
EP3120868A1 (en) 2017-01-25
CY1122913T1 (el) 2021-10-29
US10227381B2 (en) 2019-03-12
WO2010037514A3 (en) 2010-06-03
PT3069728T (pt) 2019-02-13
US10047124B2 (en) 2018-08-14
RS60385B1 (sr) 2020-07-31
CA2936870A1 (en) 2010-04-08
DK3124043T3 (da) 2020-05-04
HRP20150223T1 (hr) 2015-06-05
SI3069728T1 (sl) 2019-03-29
EP3120868B1 (en) 2020-04-08
HK1159526A1 (zh) 2012-08-03
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
HUE042115T2 (hu) 2019-06-28
JP5753783B2 (ja) 2015-07-22
JP2017000148A (ja) 2017-01-05
EP2341927B1 (en) 2016-05-04
LT3069728T (lt) 2019-02-11
US20210253637A1 (en) 2021-08-19
CA2936924A1 (en) 2010-04-08
US10906936B2 (en) 2021-02-02
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
PL3111952T3 (pl) 2019-04-30
US11208434B2 (en) 2021-12-28
EP3069728A1 (en) 2016-09-21
SI3124043T1 (sl) 2020-07-31
US20160376314A1 (en) 2016-12-29
RS53782B1 (sr) 2015-06-30
WO2010037513A1 (en) 2010-04-08
PL2341927T3 (pl) 2016-11-30
DK3120870T3 (da) 2020-06-22
JP2017029135A (ja) 2017-02-09
LT3106175T (lt) 2020-08-10
WO2010037514A2 (en) 2010-04-08
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
DK3132801T3 (da) 2020-02-10
CA2739384C (en) 2017-05-02
PL3120868T3 (pl) 2020-08-24
HRP20200722T1 (hr) 2020-10-16
EA201100586A1 (ru) 2011-10-31
JP2016145210A (ja) 2016-08-12
JP6214066B2 (ja) 2017-10-18
EP3106175A1 (en) 2016-12-21
CA2936982A1 (en) 2010-04-08
PT3120870T (pt) 2020-07-01
KR102392070B1 (ko) 2022-04-29
EP3124043B1 (en) 2020-04-29
EP3120869B1 (en) 2020-07-22
HUE030296T2 (en) 2017-04-28
PT2172211E (pt) 2015-03-09
PL2331118T3 (pl) 2017-05-31
CY1122677T1 (el) 2021-03-12
EA032437B1 (ru) 2019-05-31
JP2017018101A (ja) 2017-01-26
EP3106175B1 (en) 2020-04-01
HRP20160915T1 (hr) 2016-10-07
JP2017023136A (ja) 2017-02-02
ES2607460T3 (es) 2017-03-31
CA2739387A1 (en) 2010-04-08
LT3111952T (lt) 2018-12-27
SI3111952T1 (sl) 2019-01-31
CN102170901A (zh) 2011-08-31
CY1116302T1 (el) 2017-02-08
KR20220058655A (ko) 2022-05-09
EP3120870B1 (en) 2020-04-01
PT3132801T (pt) 2020-02-04
DK3111952T3 (en) 2019-01-28
RS55531B1 (sr) 2017-05-31
KR101883426B1 (ko) 2018-07-31
UA110599C2 (uk) 2016-01-25
AU2009300087A1 (en) 2010-04-08
PL3132801T3 (pl) 2020-06-15
KR20180088494A (ko) 2018-08-03
US10047123B2 (en) 2018-08-14
BRPI0920759A2 (pt) 2016-03-08
US10941181B2 (en) 2021-03-09
EP3111952A1 (en) 2017-01-04
DK2172212T3 (da) 2016-12-19
US20130309193A1 (en) 2013-11-21
ES2802227T3 (es) 2021-01-18
CA2936920A1 (en) 2010-04-08
AU2009300087B2 (en) 2014-09-04
LT3120869T (lt) 2020-11-10
CY1121098T1 (el) 2019-12-11
US20130004456A1 (en) 2013-01-03
HUE029360T2 (en) 2017-02-28
ES2612466T3 (es) 2017-05-17
EP2331118B1 (en) 2016-10-26
EA201401104A1 (ru) 2015-05-29
US20150125478A1 (en) 2015-05-07
SI3120870T1 (sl) 2020-08-31
PT3106175T (pt) 2020-07-01
RS60381B1 (sr) 2020-07-31
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
HRP20161504T1 (hr) 2016-12-30
NZ591882A (en) 2012-12-21
EP3111952B1 (en) 2018-10-31
US20210261614A1 (en) 2021-08-26
HUE050428T2 (hu) 2020-12-28
EP2172211B1 (en) 2014-12-03
HRP20201025T8 (hr) 2022-01-07
RS60338B1 (sr) 2020-07-31
RS55043B1 (sr) 2016-12-30
ES2708654T3 (es) 2019-04-10
HUE049366T2 (hu) 2020-09-28
JP2014239681A (ja) 2014-12-25
PL3106175T3 (pl) 2020-08-24
MX2011003540A (es) 2011-06-20
CA2936869A1 (en) 2010-04-08
LT2172212T (lt) 2016-11-10
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
KR20110082155A (ko) 2011-07-18
CA2936920C (en) 2019-12-03
BRPI0920791B1 (pt) 2022-01-18
CN106986919A (zh) 2017-07-28
HRP20200988T1 (hr) 2020-10-16
ES2710608T3 (es) 2019-04-26
NZ591855A (en) 2012-11-30
AU2009300088B2 (en) 2014-09-04
HUE049364T2 (hu) 2020-09-28
CN102170900A (zh) 2011-08-31
KR20110074894A (ko) 2011-07-04
JP6294914B2 (ja) 2018-03-14
HUE031030T2 (en) 2017-06-28
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
JP6294913B2 (ja) 2018-03-14
DK3069728T3 (en) 2019-02-25
CN102170901B (zh) 2015-01-07
SI3106175T1 (sl) 2020-08-31
CA2936887A1 (en) 2010-04-08
SI2331118T1 (sl) 2017-01-31
ES2536465T3 (es) 2015-05-25
US20160355550A1 (en) 2016-12-08
LT3120868T (lt) 2020-08-10
HUE051030T2 (hu) 2021-01-28
RS58229B1 (sr) 2019-03-29
SI3132801T1 (sl) 2020-03-31
CA2936982C (en) 2019-12-03
US20210238227A1 (en) 2021-08-05
US20120141517A1 (en) 2012-06-07
EP3132801A1 (en) 2017-02-22
KR20160103558A (ko) 2016-09-01
US8653035B2 (en) 2014-02-18
PT3111952T (pt) 2019-02-05
PL3120870T3 (pl) 2020-07-27
UA103202C2 (ru) 2013-09-25
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
HRP20200110T1 (hr) 2020-05-15
KR20200085381A (ko) 2020-07-14
EP2341927A2 (en) 2011-07-13
CY1119744T1 (el) 2018-06-27
AU2009300088A1 (en) 2010-04-08
US10046037B2 (en) 2018-08-14
HRP20201015T1 (hr) 2020-10-16
CY1123089T1 (el) 2021-10-29
JP6150859B2 (ja) 2017-06-21
ES2819244T3 (es) 2021-04-15
RS60386B1 (sr) 2020-07-31
CA2936869C (en) 2019-08-06
ES2804723T3 (es) 2021-02-09
US20210347822A1 (en) 2021-11-11
US20160376317A1 (en) 2016-12-29
CY1118702T1 (el) 2017-07-12
DK3120869T3 (da) 2020-08-10
EP3069728B1 (en) 2018-11-14
CA2936870C (en) 2019-11-26
ES2584245T3 (es) 2016-09-26
CA2739384A1 (en) 2010-04-08
KR101687840B1 (ko) 2016-12-19
LT3132801T (lt) 2020-02-10
ES2788129T8 (es) 2020-11-04
HK1161106A1 (en) 2012-08-24
HRP20201015T8 (hr) 2022-01-21
JP2012504563A (ja) 2012-02-23
EP3120870A1 (en) 2017-01-25
CY1123098T1 (el) 2021-10-29
CA2936868A1 (en) 2010-04-08
EP2172212A2 (en) 2010-04-07
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
CY1123113T1 (el) 2021-10-29
HRP20170115T1 (hr) 2017-03-24
US8318677B2 (en) 2012-11-27
PT2341927T (pt) 2016-08-02
PT3120869T (pt) 2020-09-22
SI3120869T1 (sl) 2020-10-30
MX2011003539A (es) 2011-06-20
HUE041446T2 (hu) 2019-05-28
JP2012504393A (ja) 2012-02-23
EP2331118A1 (en) 2011-06-15
US9993540B2 (en) 2018-06-12
EP2172212A3 (en) 2010-04-14
CY1121258T1 (el) 2020-05-29
CY1123526T1 (el) 2022-03-24
PT3124043T (pt) 2020-05-12
PT2172212T (pt) 2016-12-22
US20100158931A1 (en) 2010-06-24
MX338294B (es) 2016-04-11
CA2936924C (en) 2019-07-16
SI2172212T1 (sl) 2016-12-30
PL2172211T3 (pl) 2015-05-29
US12221493B2 (en) 2025-02-11
US20160376315A1 (en) 2016-12-29
BRPI0920791B8 (pt) 2022-02-15
TR201900809T4 (tr) 2019-02-21
EP2172212B1 (en) 2016-10-05
US20170326217A1 (en) 2017-11-16
PL3124043T3 (pl) 2020-07-27
JP2016047825A (ja) 2016-04-07
PT2331118T (pt) 2017-02-06
DK2172211T3 (en) 2015-02-16
US20160376313A1 (en) 2016-12-29
HUE047365T2 (hu) 2020-04-28
HUE049367T2 (hu) 2020-09-28
LT2331118T (lt) 2016-12-27
JP5883476B2 (ja) 2016-03-15
US12234298B2 (en) 2025-02-25
PT3120868T (pt) 2020-07-16
US20160376316A1 (en) 2016-12-29
EA023013B1 (ru) 2016-04-29
EP3132801B1 (en) 2019-10-30
HRP20190202T1 (hr) 2019-03-22
CA2936868C (en) 2019-10-22
KR102133402B1 (ko) 2020-07-14
CA2936887C (en) 2019-11-12
EP3120869A1 (en) 2017-01-25
DK2331118T3 (da) 2017-01-09
DK3120868T3 (da) 2020-06-22
ES2770090T3 (es) 2020-06-30
US8961985B2 (en) 2015-02-24
EP2172211A1 (en) 2010-04-07
DK2341927T3 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
TR201900852T4 (tr) Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşı yeni immünoterapi.
TR201909021T4 (tr) Çeşitli nöronal tümörlere ve beyin tümörlerine karşı kişiselleştirilmiş immünoterapi.
AU2014271235A1 (en) Novel immunotherapy against several tumors including neuronal and brain tumors
AU2016204711B2 (en) Novel immunotherapy against several tumors including neuronal and brain tumors